Identification and susceptibility evaluation of Candida yeasts due to the optimization of ciclopiroxolamine release from mucoadhesive oral tablets

Česká verzia

Authors: E. Mašková ¹; J. Mašek ^1,2; J. Gajdziok ¹; M. Rabišková ¹
Authors place of work: Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav technologie léků ¹; Veterinární a farmaceutická univerzita Brno, Výzkumný ústav veterinárního lékařství, Oddělení farmakologie a toxikologie ²
Published in the journal: Čes. slov. Farm., 2010; 59, 79-86
Category: Původní práce

Summary

Oral candidosis represents a difficult and often recidivating complication in immunodeficient patients. Oral mucoadhesive tablets with prolonged release of a locally acting antifungal drug, e.g. ciclopiroxolamine, could contribute to their pharmacotherapy. For efficient therapy, the drug concentration present in oral cavity has to be determined, i.e. the drug content in the dosage form and its release have to be formed. The Theoretical Part of this paper aims to describe the basic characteristics of Candida yeasts and their induction of oral candidosis, to the possibilities of using standardized methods for detecting and determining their susceptibility to antifungal agents. The Experimental Part is focused on the establishment, identification and quantification of Candida species represented in 536 patients by cultivation on chromogenic agar. The microdilution and disc diffusion methods have been used for assessing the susceptibility of isolated and reference strains of yeasts to the antifungal drug – ciclopiroxolamine. The obtained results showed that 65.96% of candidosis are caused by Candida albicans, however the other tested species of Candida involve the disease only in minor part (C. tropicalis 12.76%, C. glabrata 10.64%, C. parapsilosis 10.64%). The microdilution method established the minimum inhibitory concentration for the reference strains of Candida to 2 μg/ml of ciclopiroxolamine for Candida glabrata, 1 μg/ml for Candida albicans and Candida tropicalis, and 0.5 μg/ml for Candida parapsilosis. Theoretical ciclopiroxolamine content in a tablet providing exceeding MIC for the tested species of Candida for 8–10 hours should lie, when considering all influencing factors, in the range of 25–50 mg with a release rate of 0.24 mg per hour at the minimum.

Key words:
oral candidosis – ciclopiroxolamine – microbiological establishment – pathogen susceptibility evaluation – oral mucoadhesive tablets

Zdroje

1. Dvořáčková, K.: Principy uvolňování léčiv z perorálních matricových tablet obsahujících hypromelosu. Chem. listy, 2009; 103, 66–72.

2. Dostálová, M., Rabišková, M.: Mukoadhezivní orální tablety – moderní léková forma s řízeným uvolňováním léčiva. Čes. slov. Farm., 2000; 2, 55–61.

3. Bajerová, M., Krejčová, K., Rabišková, M., Gajdziok, J., Masteiková, R.: Oxycellulose – significant characteristics in relation to its pharmaceutical and medici applications, Adv. Polym. Technol., 2009; 28, 199–208.

4. Niewerth, M., Kunze, D., Seibold, M.: Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors. Antimicrob. Agents Chemother., 2003; 47, 1805–1817.

5. Český lékopis, Praha, Grada Publishing, 2005, 7348 s.

6. Hui, X., Wester, R. C., Barbadillo, S.: Ciclopirox Delivery into the Human Nail Plate. J. Pharm. Sci., 2004; 93, 2545–2548.

7. Martindale, The complete drug reference. In: Sweetman, S.C. eds., Pharmaceutical press, 2002; 33, 52-63.

8. Švihovec, J., Novotná, H.: Pharmindex Kompendium 2001. Český Těšín: MediMedia, 2001, 1802 s.

9. Gupta, A. K., Bluhm, R.: Ciclopirox (Loprox) gel for superficial fungal infections. Skin Ther. Lett., 2004; 9, 4–9.

10. Shilova, I. B., Guskova, T. A., Glushkov, R. G.: Modern drugs for treating dermatomycosis. Pharm. Chem. J., 2004; 38, 175–180.

11. Niewerth, M., Schiller, N.: Wirkungsweise von Ciclopiroxolamin auf Candida albicans. Mycoses, 2002; 45, 63–68.

12. Tarawneh, R. T., Imad, I.: Physicochemical studies on Ciclopiroxolamine complexes with divalent metal ions. Int. J. Pharm., 2005; 289, 179–187.

13. Polak, A., Jackel, A., Noack A.: Agar-Sublimations-Test zur In vitro-Bestimmung der antimykotischen Aktivität von Morpholin-Derivaten. Mycoses, 2004; 47, 184–192.

14. Cannon, R. D., Chaffin, W. L.: Oral colonization by Candida albicans. Crit. Rev. Oral. Biol. Med., 1999; 10, 359–383.

15. Cannon, R. D., Holmes, A. R., Mason, A. B., Monk, B. C.: Oral Candida: Clearance, Colonization, or Candidiasis? J. Dent. Result, 1995; 74, 1152–1161.

16. Figueiredo, V. T., Santos, D., Resende, M. A., Hamdan, J. S.: Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infection. Mycopathologia, 2007; 164, 27–33.

17. Jedličková, A.: Systémové mykózy. 1. vyd. Praha: Maxdorf 2006, 24–49.

18. Soysa, N. S., Samaranayake, L. P., Ellepola, A.: Antimicrobials as a contributory factor in oral candidosis – a brief overview. Oral Dis., 2008; 14, 138–143.

19. Haber, J.: Systémové mykózy a jejich léčba. Praha: Galén, 1995, 19–53.

20. http://www.ma.uni-heidelberg.de/inst/imh/myko_2/n_ myco1.html (20. 11. 2009).

21. Votava, M.: Lékařská mikrobiologie obecná. Praha: Neptun 2001, 163–164.

22. Karaca, N., Koc, N.: In vitro susceptibility testing of dermatohytes: comparison of disk diffusion and reference broth dilution methods. Diagn. Microbiol. Infect. Dis., 2004; 48, 259–264.

23. Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S.: Activities of micafungin against 315 Invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol., 2006; 44, 324–326.

24. Pfaller, M. A., Messer, S. A., Boyken, L.: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis., 2004; 48, 201–205.

25. Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S.: Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-Recommended broth microdilution methods. J. Clin. Microbiol., 2007; 45, 70–75.

26. Bille, J.: Biomic video reading of fluconazole agar disk diffusion susceptibility testing of Candida spp. Clinical izolates compared to NCCLS microbroth dilution. ICAAC poster J-120; S. Diego, CA, 1998.

27. Barry, A., Brown S.: Fluconazole Disk Diffusion Procedure for Determining Susceptibility of Candida Species. J. Clin. Microbiol., 1996; 34, 2154–2157.

28. Pfaller, M. A., Boyken, L., Messer, S. A., Tendolaker, S.: Comparison of results of voriconazol disk diffusion testing for Candida species with results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol., 2005; 43, 5208–5213.

29. Pfaller, M. A., Hazen, K. C., Boyken, L., Messer, S. A., Tendolaker, S.: Comparison of results of fluconazol disk diffusion testing for Candida species with results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol., 2004; 42, 3607–3612.

30. Shojaei, A. H.: Buccal mucosa as a route for systemic drug delivery: a review. Journal of Pharmacy and Pharmaceutical Sciences J. Pharm. Pharm. Sci., 1998; 1, 15–30.